Pathology, National Health Laboratory, Asmara, Eritrea.
Microbiology, National Health Laboratory, Asmara, Eritrea.
Sci Rep. 2020 Jun 4;10(1):9099. doi: 10.1038/s41598-020-66096-5.
The main objective of this study was to investigate the incidence of cervical (C53), ovarian (C56) and uterine (C54-55) cancers in pathology department of the National Health Laboratory of Eritrea between 2011 and 2017. All tumour positive cases from cervix, ovary and uterus diagnosed between 2011 and 2017 were analyzed, based on the data from the pathology department available in National Health Laboratory. We summarized the results by using crude incidence rates (CIR) and age-standardized rates (ASRs). Annual percentage changes (APCs) for each site were calculated and compared according to ten-year age difference and year of occurrence. Between 2011 and 2017, 883 cases of cervical, ovarian and uterine tumours were reported in Eritrea. Malignant and benign tumours/entities comprising 269 and 614, respectively. The ASR for malignant tumours was highest in women aged between 60-69 (6.84 per 100 000). Total ASR for specific gynecological cancers (cervical, ovarian, uterine) was 19.32 per 100 000 females. The ASR for cervical cancer over the study period was 8.7 per 100 000. The ASR for ovarian and uterine cancers were 6.75 per 100 000 and 5.14 per 100 000, respectively. Over the study period, the incidence of these cancers was largely stable with no significant change in incidence rates recorded. In sum, the ASR for cervical cancer is relatively low compared to the rates reported in the region. Further, the ASR for ovarian and uterine cancers is nearly similar to the rates observed in this region. The study also provides ample evidence on the need for research targeted at uncovering the true burden of gynecological cancers in Eritrea. Potential solutions will require the establishment of high-quality population-based cancer registries (PBCRs) and long-term commitment to improvements in research platforms, training, screening, diagnosis, and the overall management of cancers in the country.
本研究的主要目的是调查 2011 年至 2017 年期间厄立特里亚国家卫生实验室病理科的宫颈癌（C53）、卵巢癌（C56）和子宫癌（C54-55）的发病率。根据国家卫生实验室病理学部门的数据，对 2011 年至 2017 年间诊断为宫颈癌、卵巢癌和子宫癌的所有阳性肿瘤病例进行了分析。我们使用粗发病率（CIR）和年龄标准化率（ASR）总结了结果。根据十年的年龄差异和发病年份，计算并比较了每个部位的年百分比变化（APC）。2011 年至 2017 年间，厄立特里亚报告了 883 例宫颈癌、卵巢癌和子宫癌病例。恶性和良性肿瘤/实体瘤分别为 269 例和 614 例。60-69 岁女性的恶性肿瘤 ASR 最高（每 100000 人 6.84 例）。特定妇科癌症（宫颈癌、卵巢癌、子宫癌）的总 ASR 为每 100000 名女性 19.32 例。研究期间宫颈癌的 ASR 为每 100000 人 8.7 例。卵巢癌和子宫癌的 ASR 分别为每 100000 人 6.75 例和 5.14 例。研究期间，这些癌症的发病率基本保持稳定，发病率无明显变化。总的来说，与该地区报告的比率相比，宫颈癌的 ASR 相对较低。此外，卵巢癌和子宫癌的 ASR 与该地区观察到的比率相近。该研究还提供了充分的证据，表明需要针对揭示厄立特里亚妇科癌症真实负担的研究，潜在的解决方案将需要建立高质量的基于人群的癌症登记处（PBCR），并长期致力于提高研究平台、培训、筛查、诊断和国家癌症的整体管理水平。
